As a result, some scientists think this drug holds promise in treatment of K2 withdrawal. One case research revealed in 2014 uncovered that Naltrexone, an opioid receptor antagonist made use of to take care of opioid dependancy, helped decrease cravings for artificial cannabinoids.And when Shahwan went AWOL on their $four million agreement in 2013,